Implied Podcast

Summit Therapeutics (NASDAQ: SMMT) just lost a quarter of its value in one day after disappointing follow-up data on its lung cancer drug sent investors running. In this 3-minute breakdown, we cut through the noise: why trial results that looked promising in China fell flat in Western populations, why the FDA may slam the brakes on approval, and how Summit’s cash burn adds another layer of risk. I...

Broadcom just shocked Wall Street: Q3 revenue surged 22% to $15.95B, with AI sales exploding 63% to $5.2B. But the real headline? A $10 billion AI chip order—widely believed to be from OpenAI—that could reshape the industry. In this quick, three-minute breakdown, we cut past the headlines to unpack what’s really implied: how AI now makes up a third of Broadcom’s business, why this secret mega-deal...

Lululemon just shocked Wall Street: the stock plunged 16–17% in a single day—even after beating earnings. In this 3-minute episode of Implied , we unpack what’s really going on behind the numbers. From flat U.S. sales and mounting tariff pressures to a risky push for more “new styles,” the story is bigger than a simple outlook cut. Is Lululemon reinventing itself—or risking its premium edge? Tune...

Figma just delivered a strong debut as a public company: 41% revenue growth, rare net income, healthy cash flow, and over $1.6B in the bank. So why did the stock crash nearly 20%? In this 10-minute episode of Implied , we dig past the headlines to uncover the real story: sky-high expectations, cautious guidance, and a $67B valuation that leaves no room for error. We’ll unpack what’s solid, what’s...

Salesforce just dropped Q2 FY26 earnings—and the headlines only tell half the story. Revenue hit $10.2B, EPS beat expectations, and AI/Data Cloud ARR surged 120% to $1.2B. Sounds great, right? Yet the stock fell 6–8%. In this 10-minute deep dive, we unpack why Wall Street isn’t impressed, what Salesforce’s cautious Q3 guidance really signals, and whether AI can scale fast enough to reignite growth...

Asana just crossed 150,000 paying customers worldwide —but the real story is what’s happening beneath the surface. In this sharp 10-minute breakdown, we cut through the numbers from Q2 fiscal 2026 to unpack what’s implied but not said: Enterprise accounts are surging, carrying growth while small-business momentum may be stalling. R&D spending still burns at ~40% of revenue—an all-in bet to out...